Web Exclusives

A recent review of liquid biopsy studies found it useful in detecting circulating tumor DNA in patients with early and select advanced non–small cell lung cancer.

A recent review discussed multiple ongoing studies evaluating KRAS G12C inhibitors for the treatment of non–small cell lung cancer harboring the KRAS G12C mutation.

Bispecific antibodies are unique antibody constructs that simultaneously bind 2 antigens, typically targeting an antigen on myeloma cells and a molecule on an immune cell. By using the patient’s immune system to destroy the malignant plasma cells, bispecific antibodies offer a promising treatment to overcome immunosuppression for patients with relapsing/refractory MM (RRMM).⁴

A recent study demonstrates liquid biopsy has high concordance to tissue biopsy in non–small-cell lung cancer, making it an acceptable first-line testing option.

A small study of patients with non–small-cell lung cancer with brain metastasis showed sotorasib had promising efficacy on brain lesions.

A recent retrospective analysis of patients with non–small-cell lung cancer harboring KRAS mutations found immune checkpoint inhibitors have benefit in first- and second-line treatment among KRAS subtypes.

A large retrospective chart review found a short median progression-free survival in patients with non–small-cell lung cancer harboring the KRAS G12C mutation who were treated with docetaxel with or without ramucirumab.

Biomarker testing is associated with improved overall survival in patients with advanced non–small-cell lung cancer, but disparities in access to testing persist.

A review of treatments and clinical studies for non–small-cell lung cancer harboring the KRAS G12C mutation finds encouraging overall survival results.

Palliative care is underused by Black and Hispanic/Latinx patients with advanced non–small-cell lung cancer.

Evaluation of flat-dose nivolumab plus weight-based ipilimumab in patients with advanced non–small-cell lung cancer and poorer prognosis demonstrates efficacy with a tolerable safety profile.

A recent study assessing the prognostic value of circulating tumor cells in patients with lung cancer found an association with poorer patient outcomes, with more pronounced effect on small-cell lung cancer.

Based on positive results of the KRYSTAL-1 clinical trial, adagrasib was granted accelerated FDA approval for patients with non–small-cell lung cancer harboring the KRAS G12C mutation.

A recent study from the United Kingdom in younger adults with non–small-cell lung cancer found poor survival outcomes in patients without targetable mutations.

A recent review presents updated treatment strategies for patients with non–small-cell lung cancer harboring the KRAS G12C mutation.

A review of multiple clinical trials in patients with non–small-cell lung cancer and brain metastases finds adagrasib effectively penetrates the central nervous system, resulting in good response rates.

Study determines that permanently discontinuing immune checkpoint inhibitors after grade ≥2 immune-related adverse events is an appropriate response for patients with stage IV non–small-cell lung cancer.

In patients with non–small-cell lung cancer, broad and rapid genomic profiling are recommended for use at all stages of clinical management to improve patient outcomes.

Sotorasib in a patient with KRAS G12C–mutated lung cancer and brain metastases resolved or shrank brain lesions and improved mental status.

A guide to the departments and people you should be working with to collect the data pertinent to your navigation program.

Navigators in the Metric Pilot Study increased the number of palliative care referrals through the use of a symptom assessment tool and worked together to improve the assessment process.

In a recent study, circulating tumor cells were found to act as a precise biomarker in early assessment and therapy monitoring in patients with lung cancer.

Despite advantages for molecular testing for non–small-cell lung cancer, the testing rate remains low, with white patients and female patients having a higher likelihood of undergoing molecular testing.

Maintaining quality of life and independence was found to be a high priority for patients with non–small-cell lung cancer and should be regularly assessed by the care team.

All patient ethnic/racial groups demonstrated improved clinical outcome when experiencing immune-related adverse events while receiving therapy with an immune checkpoint inhibitor, but Hispanic patients appear to derive less benefit.

In a recent trial of patients with advanced non–small-cell lung cancer, liquid biopsy led to faster molecular results and shortened time to treatment.

CodeBreak 200 phase 3 trial results demonstrated that sotorasib achieved a more robust survival benefit versus docetaxel in patients with advanced non–small-cell lung cancer harboring KRAS G12C mutation.

Biomarker testing is the standard of care in advanced non–small-cell lung cancer, but the rate of patients receiving test results prior to initiating treatment is low.

Study finds that frequencies of mutations commonly found in patients with non–small-cell lung cancer vary among members of 3 racial groups.

Study of patients with lung adenocarcinoma found that patients with KRAS G12C mutation and high PD-L1 expression benefit more from immunotherapy compared with patients with other KRAS mutations.